Section 12: Key Points
What We've Covered
This section made the following main points:
What We've Covered
This section made the following main points:
- Biotransformation is the process by which a substance changes from one chemical to another (transformed) by a chemical reaction within the body.
 - Biotransformation is vital to survival because it transforms absorbed nutrients into substances required for normal body functions.
 - Potential complications of biotransformation include:
- Detoxification — biotransformation results in metabolites of lower toxicity than the parent substance.
 - Bioactivation — biotransformation results in metabolites of greater toxicity than the parent substance.
 
 - Chemical reactions continually occur in the body to build up new tissue, tear down old tissue, convert food to energy, dispose of waste materials, and eliminate toxic xenobiotics.
 - Enzymes are catalysts for nearly all biochemical reactions in the body; essential biotransformation reactions would be slowed or prevented without these enzymes, causing major health problems.
 - There are generally three types of enzyme specificity:
- Enzymes with absolute specificity catalyze only one reaction.
 - Enzymes with group specificity act only on molecules that have specific functional groups.
 - Enzymes with linkage specificity act on a particular type of chemical bond regardless of the rest of the molecular structure.
 
 - There are two biotransformation reaction phases:
- Phase I reactions modify the chemical by adding a functional structure, allowing the substance to "fit" into a second (Phase II) enzyme:
- Oxidation — the substrate loses electrons.
 - Reduction — the substrate gains electrons.
 - Hydrolysis — the addition of water splits the toxicant into two fragments or smaller molecules.
 
 - Phase II reactions conjugate (join together) the modified xenobiotic with another substance. The most important Phase II reactions are:
- Glucuronide conjugation, a high-capacity pathway — glucuronic acid is added directly to the toxicant or its Phase I metabolite, generally resulting in hydrophilic conjugates excreted by the kidney or bile.
 - Sulfate conjugation, a low-capacity pathway — decreases the toxicity of xenobiotics, resulting in highly polar sulfate conjugates readily secreted in the urine.
 
 
 - Phase I reactions modify the chemical by adding a functional structure, allowing the substance to "fit" into a second (Phase II) enzyme:
 - Biotransformation sites are the:
- Liver (primary site, which also makes it the most susceptible to damage by ingested toxicants).
 - Kidneys (about 10-30% of the liver's capacity).
 - Skin, intestines, testes, and placenta (low capacity).
 
 - Biotransformation effectiveness depends on factors that can inhibit or induce enzymes and dose levels, including species, age, gender, genetic variability, nutrition, disease, exposure to other chemicals, and the dose level.